Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336748 | 1.00 | ENPP1 (0.47) | ENPP1ROCK1ROCK2NAMPTALDH1A1 | |
| SCHEMBL30337022 | 0.89 | ENPP1 (0.42) | ENPP1ROCK1ROCK2ALDH1A1 | |
| SCHEMBL30088818 | 0.89 | ENPP1 (0.42) | ENPP1ROCK1ROCK2ALDH1A1 | |
| SCHEMBL24000619 | 0.89 | ENPP1 (0.42) | ENPP1ROCK1ROCK2ALDH1A1 | |
| SCHEMBL30088988 | 0.85 | ENPP1 (0.67) | ENPP1ALDH1A1MAPK1KMT2AHPGD | |
| SCHEMBL25548011 | 0.85 | ENPP1 (0.67) | ENPP1ALDH1A1MAPK1KMT2AHPGD | |
| SCHEMBL24000534 | 0.81 | ROCK2 (0.56) | ROCK1ROCK2NAMPT | |
| SCHEMBL24000309 | 0.79 | ENPP1 (0.67) | ENPP1ROCK1ROCK2NAMPTALDH1A1 | |
| SCHEMBL24804969 | 0.79 | TARS1 (0.66) | ENPP1ROCK1 | |
| SCHEMBL30151465 | 0.79 | TARS1 (0.66) | ENPP1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515939-A | Novel phthalazine derivatives having an inhibitory activity on ectonucleotide pyrophosphatase-phosphodiesterase and their use | 谛希诺生物科技有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115515939-B | Novel phthalazine derivatives having activity of inhibiting exonucleotide pyrophosphatase-phosphodiesterase and their use | 谛希诺生物科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2023-05-25 | — | — | US | disclosed |
| CN-115515939-A | Novel phthalazine derivatives having an inhibitory activity on ectonucleotide pyrophosphatase-phosphodiesterase and their use | 谛希诺生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885ROCK1 1268/4885ROCK2 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.